15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 15 firms covering Madrigal Pharmaceuticals Inc, 14 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $485.00 to $964.00, a moderate spread. The average target of $662.43 sits 23% above the current $538.04. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 12 to 14 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.03 next quarter toward $12.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 ratings
Strong Buy
Strong Buy00%
Buy1493%
Hold17%
Sell00%
Strong Sell00%
Based on 15 analysts giving stock ratings to Madrigal Pharmaceuticals Inc.
As of Jul, 14 of 15 firms rate MDGL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MDGL EPS & revenue forecast
EPS · NEXT QUARTER
$-1.03
Range $-1.42 – $-0.82 · 3 analysts · -79% YoY
Next period, 3 analysts expect Madrigal Pharmaceuticals Inc to earn $-1.03 a share (range $-1.42 – $-0.82), versus $-4.96 a year earlier. Full-year consensus is $-6.52, growing to $12.38 the year after.
REVENUE · NEXT QUARTER
$393.4M
Range $381.3M – $407.9M · 3 analysts · +37% YoY
Revenue is expected to reach $393.4M (range $381.3M – $407.9M), +37.0% year-over-year. Full-year consensus is $1.5B, rising to $2.2B next year.
Top analysts covering Madrigal Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MDGL.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$560.00+4.1% to target
Overall win rate
53%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$620.00+15.2% to target
Overall win rate
46%
+ Follow
#3
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$745.00+38.5% to target
Overall win rate
44%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$900.00+67.3% to target
Overall win rate
34%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #302
Buy
$650.00+20.8% to target
Overall win rate
32%
+ Follow
MDGL stock forecast FAQ
What is MDGL's average 12-month price target?+
The 14 analysts with a live target average $662.43 for Madrigal Pharmaceuticals Inc over the next 12 months, ranging from a $964.00 high to a $485.00 low.
Is MDGL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 15 analyst ratings, 14 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MDGL?+
The Street-high target is $964.00 (Barclays), and the Street-low is $485.00 (JMP Securities). The average of all 14 active targets is $662.43.
How many Wall Street analysts cover MDGL?+
15 analysts have an active rating on Madrigal Pharmaceuticals Inc, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering MDGL?+
Among analysts who currently cover MDGL, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $560.00 target.
What is Madrigal Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.03 per share (range $-1.42 – $-0.82) across 3 analysts. Full-year EPS is projected at $-6.52, rising to $12.38 the following year.
How much revenue is Madrigal Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $393.4M (range $381.3M – $407.9M). Full-year revenue is projected at $1.5B, growing to $2.2B next year.
Have analysts been upgrading or downgrading MDGL lately?+
As of Jul, 14 of 15 firms rate MDGL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MDGL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
